ResMed Inc. reported its fourth-quarter earnings for fiscal year 2024, revealing a revenue increase of 9% to $1.2 billion, or 10% on a constant currency basis. The company's diluted earnings per share (EPS) stood at $1.98, while its non-GAAP diluted EPS was reported at $2.08, reflecting a 30% year-over-year increase. ResMed's gross margin improved by 350 basis points to 58.5%, with the non-GAAP gross margin rising by 330 basis points to 59.1%. The strong performance was attributed to steady demand for its sleep apnea treatment devices, aligning with market estimates. For the full fiscal year, ResMed's total revenues reached $4.69 billion.